CDT Equity Notes Sarborg Patent Filing for Two Cystic Fibrosis Compounds Using Agentic AI Platform

A substance of matter patent filed in under three weeks signals a measurable shift in how agentic AI platforms may compress IP generation timelines in rare disease programs. CDT Equity Inc. (Nasdaq: CDT) has noted the filing by its portfolio company Sarborg Limited of a new SOM patent covering two established compounds in the cystic fibrosis market, with the work completed using Sarborg's Signature Agent and Multi-Agent platform backed by its 1,600 Disease Database and 1,700 Rare Disease Database.

For drug development and regulatory affairs leads, the filing's compressed timeline is the operative detail. Sarborg reports the patent was generated and filed in less than three weeks, a pace that, if reproducible across additional indications, would materially alter how small biopharmaceutical organisations approach IP strategy for repositioning candidates. The platform's stated capability covers identification of new indications and combination strategies, not only primary compound claims.

CDT holds a 20% equity stake in Sarborg and is actively evaluating its own asset portfolio against Sarborg's platform outputs, including potential combination therapies involving CDT compounds and those covered by the newly filed patent. The stated objective is to expand CDT's IP position through this data-driven repositioning approach rather than through conventional discovery timelines.

The cystic fibrosis market carries well-documented competitive and regulatory complexity, with 21 CFR Part 211 and ICH Q10 quality system expectations applying to any downstream development activity. Whether agentic AI-generated IP translates into viable development candidates will depend on subsequent preclinical and clinical validation, and on the robustness of the patent claims under examination. The SOM filing represents an early-stage IP event, not a regulatory submission or approved therapeutic.

CDT has indicated it intends to apply this approach more broadly across its portfolio, with licensing and strategic partnerships named as near-term commercial mechanisms. The measurable checkpoint will be whether the cystic fibrosis SOM patent survives examination and whether combination therapy candidates identified through the platform advance into formal development programs.

Source: GlobeNewswire via CDT Equity Inc. press release, 7 May 2026.